Normalization of Glucose Concentrations and Deceleration of Gastric Emptying after Solid Meals during Intravenous Glucagon-Like Peptide 1 in Patients with Type 2 Diabetes
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
The effects of different i.v. doses of glucagon-like peptide 1 (GLP-1) on glucose homeostasis and gastric emptying were compared in patients with type 2 diabetes. Twelve patients with type 2 diabetes received three different infusion rates of GLP-1 (0.4, 0.8, and 1.2 pmol/kg x min) or placebo in the fasting state and after a solid test meal (containing [(13)C]octanoic acid). Blood was drawn for glucose, insulin, C-peptide, glucagon, and GLP-1 determinations. The gastric emptying rate was calculated from the (13)CO(2) excretion rates in breath samples. Statistics were determined using repeated measures ANOVA and Duncan's post hoc test. Plasma glucose concentrations were equally normalized with all GLP-1 doses (P < 0.001). Insulin and C-peptide concentrations dose-dependently rose during GLP-1 infusion in the fasting state (P < 0.05), but were dose-dependently reduced by GLP-1 after meal ingestion (P = 0.0031 and 0.0074, respectively). Glucagon secretion was suppressed with GLP-1. Gastric emptying was decelerated by GLP-1 in a dose-dependent fashion (P < 0.001). Despite a dose-dependent stimulation of insulin secretion, glucose normalization can be achieved even with 0.4 pmol GLP-1/kg x min. Due to the dose-dependent inhibition of gastric emptying, lower GLP-1 doses than previously used may be as suitable for glucose control in patients with type 2 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This dosing regimen produced supraphysiological plasma levels and normalized blood glucose concentrations in type II DM (23).”
From Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans (2008) · cites this paper as [23]
In the citing paper
“The inhibitory effect of GLP-1 on gastric emptying is dose-dependent, and the use of lower doses of GLP-1 in patients with T2DM may also be suitable for blood glucose control (141).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [141]
In the citing paper
“The inhibitory effect of GLP-1 on gastric emptying is dose-dependent, and the use of lower doses of GLP-1 in patients with T2DM may also be suitable for blood glucose control (141).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [141]
In the citing paper
“Furthermore, the action of GLP-1 and GLP-1 RAs (especially short acting) on gastric and intestinal cells causes, respectively, the deceleration of gastric emptying [31] and the reduction in intestine motility [32], which both impact the absorption of nutrients.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [31]
Citations
Cites
Intensive insulin therapy in critically ill patients.
Van den Berghe, G., Wouters, P., Weekers, F., Verwaest, C., Bruyninckx, F., Schetz, M., Vlasselaers, D., Ferdinande, P., Lauwers, P., & Bouillon, R. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011300 · Cited by 9,977
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Self-citationZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 1×
“Nausea and vomiting have previously been reported after the administration of high GLP-1 doses in some (15, 18), but not all, studies (8, 21, 22).”
ResultSelf-citationMalmberg, K. (1997) · BMJ · doi:10.1136/bmj.314.7093.1512 · Cited by 1,286
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 3×
“However, in most previous studies comparably high doses of GLP-1 have been chosen for infusion (1, 9, 14).”
BackgroundResultSelf-citationGhoos, Y. F., Maes, B. D., Geypens, B. J., Mys, G., Hiele, M. I., Rutgeerts, P. J., & Vantrappen, G. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90640-x · Cited by 946
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Self-citationDeacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Self-citationStudies of pancreatic alpha cell function in normal and diabetic subjects
Unger, R. H., Aguilar-Parada, E., Müller, W. A., & Eisentraut, A. M. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106297 · Cited by 837
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
Self-citation
Cited by
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Self-citationBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Self-citationThe role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
“…cirrhosis and basal hyperglucagonemia (Dupre et al., 1991) and in human and animal models during euglycemic conditions (Pederson and Brown, 1978; Meier et al., 2003b), but in healthy persons under hyperglycemic conditions or in T2DM, no GIP effects on glucagon secretion were reported (Nauck et…”
BackgroundLong-term Results of Laparoscopic Sleeve Gastrectomy for Obesity
Himpens, J., Dobbeleir, J., & Peeters, G. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181e90b31 · Cited by 807
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans
van Bloemendaal, L., IJzerman, R. G., ten Kulve, J. S., Barkhof, F., Konrad, R. J., Drent, M. L., Veltman, D. J., & Diamant, M. (2014) · Diabetes · doi:10.2337/db14-0849 · Cited by 427
“GLP-1 has been shown to delay gastric emptying (45) and can induce nausea, which may also contribute to the satiety-inducing effects.”
BackgroundLauffer, L. M., Iakoubov, R., & Brubaker, P. L. (2009) · Diabetes · doi:10.2337/db08-1237 · Cited by 399
BARNETT, A. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01178.x · Cited by 391
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Self-citationNauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392
“fusion rate was based on previous studies (5,14) and was selected to increase”
BackgroundMethodSelf-citationVollmer, K., Holst, J. J., Baller, B., Ellrichmann, M., Nauck, M. A., Schmidt, W. E., & Meier, J. J. (2008) · Diabetes · doi:10.2337/db07-1124 · Cited by 356
Self-citationEffects of GLP-1 on appetite and weight
Shah, M., & Vella, A. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9289-5 · Cited by 352
“GLP-1 delays gastric emptying and gut motility in healthy lean and obese subjects and patients with type 2 diabetes [15-17].”
BackgroundRelationships Between Gastric Emptying, Postprandial Glycemia, and Incretin Hormones
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2013) · Diabetes Care · doi:10.2337/dc12-1609 · Cited by 335
Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
van Bloemendaal, L., ten Kulve, J. S., la Fleur, S. E., Ijzerman, R. G., & Diamant, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0414 · Cited by 312
“GLP-1 delays gastric emptying and gut motility not only in healthy lean but also in obese subjects and patients with T2DM (Nauck et al. 1997, Naslund et al. 1998, Schirra et al. 2002, Meier et al. 2003, Little et al. 2006).”
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
“Such effects have been reported in healthy (147), obese (148), diabetic (149), and critically ill human subjects (150).”
BackgroundGlucagon-like peptide 1(GLP-1) in biology and pathology
Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288
“J Clin Endocrinol Metab 2003; 88: 2719–2725 [83]”
BackgroundInfluentialSelf-citationGlucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors
Holst, J. J., & Deacon, C. F. (2005) · Diabetologia · doi:10.1007/s00125-005-1705-7 · Cited by 288
Self-citationMeier, J. J., Gethmann, A., Götze, O., Gallwitz, B., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2006) · Diabetologia · doi:10.1007/s00125-005-0126-y · Cited by 276
“Consistent with previous reports [11, 16], GLP-1 led to suppression of the glucagon concentration (t=0 min) both under fasting conditions and after the test meal (from 210 to 300 min; Fig.”
BackgroundMethodResultInfluentialSelf-citationAlpha cell function in health and disease: influence of glucagon-like peptide-1
Dunning, B. E., Foley, J. E., & Ahrén, B. (2005) · Diabetologia · doi:10.1007/s00125-005-1878-0 · Cited by 271
Meier, J. J., Nauck, M. A., Pott, A., Heinze, K., Goetze, O., Bulut, K., Schmidt, W. E., Gallwitz, B., & Holst, J. J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.10.004 · Cited by 266
Self-citationMechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248
Glucagon-like peptide analogues for type 2 diabetes mellitus
Shyangdan, D. S., Royle, P., Clar, C., Sharma, P., Waugh, N., & Snaith, A. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006423.pub2 · Cited by 246
Deane, A. M., Nguyen, N. Q., Stevens, J. E., Fraser, R. J. L., Holloway, R. H., Besanko, L. K., Burgstad, C., Jones, K. L., Chapman, M. J., Rayner, C. K., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1503 · Cited by 238
“At 60 min, ex(9-39)NH2 increased the rise in glycemia [ex(9-39)NH2, 9.”
BackgroundInfluentialWeivoda, M. M., Chew, C. K., Monroe, D. G., Farr, J. N., Atkinson, E. J., Geske, J. R., Eckhardt, B., Thicke, B., Ruan, M., Tweed, A. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14003-6 · Cited by 230
Basu, A., Charkoudian, N., Schrage, W., Rizza, R. A., Basu, R., & Joyner, M. J. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00373.2007 · Cited by 226
Incretin-Based Therapies in Type 2 Diabetes Mellitus
Chia, C. W., & Egan, J. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2109 · Cited by 223
Meier, J. J., & Nauck, M. A. (2010) · Diabetes · doi:10.2337/db09-1899 · Cited by 215
Self-citationLittle, T. J., Pilichiewicz, A. N., Russo, A., Phillips, L., Jones, K. L., Nauck, M. A., Wishart, J., Horowitz, M., & Feinle-Bisset, C. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2220 · Cited by 212
Self-citationGastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in the Pathogenesis of Type 2 Diabetes
Nauck, M. A., Baller, B., & Meier, J. J. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s190 · Cited by 163
Self-citationVella, A., Bock, G., Giesler, P. D., Burton, D. B., Serra, D. B., Saylan, M. L., Dunning, B. E., Foley, J. E., Rizza, R. A., & Camilleri, M. (2007) · Diabetes · doi:10.2337/db07-0136 · Cited by 201
Verspohl, E. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.002 · Cited by 196
Action and therapeutic potential of oxyntomodulin
Pocai, A. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.12.001 · Cited by 191
“The delay of gastric emptying by GLP-1 has been involved in the postprandial regulation of glucose absorption [6,7].”
BackgroundIncretin hormones and type 2 diabetes
Nauck, M. A., & Müller, T. D. (2023) · Diabetologia · doi:10.1007/s00125-023-05956-x · Cited by 190
“Even low doses (leading to close to physiological plasma concentrations) have this effect and contribute to reduced post-meal glycaemic excursions [45].”
BackgroundSelf-citationGIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice
Hansotia, T., & Drucker, D. J. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.07.019 · Cited by 183
“[84] Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE,”
BackgroundRamón, J. M., Salvans, S., Crous, X., Puig, S., Goday, A., Benaiges, D., Trillo, L., Pera, M., & Grande, L. (2012) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-012-1855-0 · Cited by 181
Glucagon-like peptide 1 and its derivatives in the treatment of diabetes
Nauck, M. A., & Meier, J. J. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.07.014 · Cited by 180
Self-citationBodyweight Changes Associated with Antihyperglycaemic Agents in Type 2 Diabetes Mellitus
Hermansen, K., & Mortensen, L. S. (2007) · Drug Safety · doi:10.2165/00002018-200730120-00005 · Cited by 174
Chia, C. W., Carlson, O. D., Kim, W., Shin, Y.-K., Charles, C. P., Kim, H. S., Melvin, D. L., & Egan, J. M. (2009) · Diabetes · doi:10.2337/db08-0958 · Cited by 176
Glucagon-Like Peptide-1: Glucose Homeostasis and Beyond
Cho, Y. M., Fujita, Y., & Kieffer, T. J. (2014) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021113-170315 · Cited by 174
Bahne, E., Sun, E. W. L., Young, R. L., Hansen, M., Sonne, D. P., Hansen, J. S., Rohde, U., Liou, A. P., Jackson, M. L., de Fontgalland, D., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.93936 · Cited by 173
Self-citationUnraveling the Science of Incretin Biology
Nauck, M. A. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.012 · Cited by 168
Self-citationGastric inhibitory polypeptide does not inhibit gastric emptying in humans
Meier, J. J., Goetze, O., Anstipp, J., Hagemann, D., Holst, J. J., Schmidt, W. E., Gallwitz, B., & Nauck, M. A. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00499.2003 · Cited by 126
Self-citationvan Bloemendaal, L., Veltman, D. J., ten Kulve, J. S., Groot, P. F. C., Ruhé, H. G., Barkhof, F., Sloan, J. H., Diamant, M., & Ijzerman, R. G. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12506 · Cited by 151
“It has been shown that GLP-1 decreases gastric emptying [39], which may contribute to its satiety-inducing effects; however, it is not likely that the effects of GLP-1 receptor activation on the brain were related to differences in gastric emptying.”
BackgroundLund, A., Knop, F. K., & Vilsbøll, T. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.03.005 · Cited by 165
Basso, N., Capoccia, D., Rizzello, M., Abbatini, F., Mariani, P., Maglio, C., Coccia, F., Borgonuovo, G., Luca, M. L. D., Asprino, R., et al. (2011) · Surgical Endoscopy · doi:10.1007/s00464-011-1755-5 · Cited by 151
Meier, J. J., Kemmeries, G., Holst, J. J., & Nauck, M. A. (2005) · Diabetes · doi:10.2337/diabetes.54.7.2212 · Cited by 146
Self-citationHlebowicz, J., Hlebowicz, A., Lindstedt, S., Björgell, O., Höglund, P., Holst, J. J., Darwiche, G., & Almér, L. (2009) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26807 · Cited by 168
Self-citationInterleukin-6 Delays Gastric Emptying in Humans with Direct Effects on Glycemic Control
Lang Lehrskov, L., Lyngbaek, M. P., Soederlund, L., Legaard, G. E., Ehses, J. A., Heywood, S. E., Wewer Albrechtsen, N. J., Holst, J. J., Karstoft, K., Pedersen, B. K., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.04.008 · Cited by 135
Self-citationEffects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2011) · Experimental Diabetes Research · doi:10.1155/2011/279530 · Cited by 138
Postprandial Hypotension: A Systematic Review
Trahair, L. G., Horowitz, M., & Jones, K. L. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2014.01.011 · Cited by 141
Nauck, M. A., El-Ouaghlidi, A., Gabrys, B., Hücking, K., Holst, J. J., Deacon, C. F., Gallwitz, B., Schmidt, W. E., & Meier, J. J. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.06.020 · Cited by 137
Self-citationShan, M., Yu, S., Yan, H., Guo, S., Xiao, W., Wang, Z., Li, Z., Ding, A., Wu, Q., & Li, S. F. Y. (2017) · Molecules · doi:10.3390/molecules22101689 · Cited by 148
Impact of Gastric Emptying on Levodopa Pharmacokinetics in Parkinson Disease Patients
M??ller, T., Erdmann, C., Bremen, D., Schmidt, W. E., Muhlack, S., Woitalla, D., & Goetze, O. (2006) · Clinical Neuropharmacology · doi:10.1097/00002826-200603000-00001 · Cited by 131
Self-citationEarly Postoperative Insulin-Resistance Changes After Sleeve Gastrectomy
Rizzello, M., Abbatini, F., Casella, G., Alessandri, G., Fantini, A., Leonetti, F., & Basso, N. (2009) · Obesity Surgery · doi:10.1007/s11695-009-0017-2 · Cited by 141
Little, T. J., Doran, S., Meyer, J. H., Smout, A. J. P. M., O'Donovan, D. G., Wu, K.-L., Jones, K. L., Wishart, J., Rayner, C. K., Horowitz, M., et al. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00099.2006 · Cited by 130
Bose, M., Oliván, B., Teixeira, J., Pi-Sunyer, F. X., & Laferrère, B. (2009) · Obesity Surgery · doi:10.1007/s11695-008-9696-3 · Cited by 128
Chelikani, P. K., Haver, A. C., & Reidelberger, R. D. (2005) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00870.2004 · Cited by 128
Gut-liver interaction in triglyceride-rich lipoprotein metabolism
Xiao, C., Hsieh, J., Adeli, K., & Lewis, G. F. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00178.2011 · Cited by 127
Phillips, L. K., & Prins, J. B. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06491.x · Cited by 119
Goetze, O., Wieczorek, J., Mueller, T. J., Przuntek, H., Schmidt, W. E., & Woitalla, D. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.11.007 · Cited by 116
Self-citationGLP‐1 based therapies: differential effects on fasting and postprandial glucose
Fineman, M. S., Cirincione, B. B., Maggs, D., & Diamant, M. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01560.x · Cited by 113
El-Ouaghlidi, A., Rehring, E., Holst, J. J., Schweizer, A., Foley, J., Holmes, D., & Nauck, M. A. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1932 · Cited by 114
Self-citationGodinho, R., Mega, C., Teixeira-de-Lemos, E., Carvalho, E., Teixeira, F., Fernandes, R., & Reis, F. (2015) · Journal of Diabetes Research · doi:10.1155/2015/806979 · Cited by 109
Relationship between glycemic control and gastric emptying in poorly controlled type 2 diabetes
Bharucha, A. E., Kudva, Y., Basu, A., Camilleri, M., Low, P. A., Vella, A., & Zinsmeister, A. R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.06.034 · Cited by 105
Effects of Diet Soda on Gut Hormones in Youths With Diabetes
Brown, R. J., Walter, M., & Rother, K. I. (2012) · Diabetes Care · doi:10.2337/dc11-2424 · Cited by 105
Meier, J. J., Gethmann, A., Nauck, M. A., Götze, O., Schmitz, F., Deacon, C. F., Gallwitz, B., Schmidt, W. E., & Holst, J. J. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00576.2005 · Cited by 104
“THE GUT HORMONE glucagon-like peptide-1 (GLP-1) lowers postprandial glucose concentrations via modulating endocrine pancreatic secretion and by decelerating the velocity of gastric emptying (10, 14, 22, 34).”
BackgroundMethodResultInfluentialSelf-citationDeane, A. M., Chapman, M. J., Fraser, R. J. L., Summers, M. J., Zaknic, A. V., Storey, J. P., Jones, K. L., Rayner, C. K., & Horowitz, M. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181d9d87a · Cited by 104
Preserved Inhibitory Potency of GLP-1 on Glucagon Secretion in Type 2 Diabetes Mellitus
Hare, K. J., Knop, F. K., Asmar, M., Madsbad, S., Deacon, C. F., Holst, J. J., & Vilsbøll, T. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0921 · Cited by 102
Self-citationZarrinpar, A., & Loomba, R. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12084 · Cited by 103
Bharucha, A. E., Charkoudian, N., Andrews, C. N., Camilleri, M., Sletten, D., Zinsmeister, A. R., & Low, P. A. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00153.2008 · Cited by 98
GLP-1 based therapy for type 2 diabetes
Arulmozhi, D. K., & Portha, B. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.01.003 · Cited by 115
Glucagon-like peptides 1 and 2 in health and disease: A review
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2013) · Peptides · doi:10.1016/j.peptides.2013.01.014 · Cited by 100
Dietary Flavonoids for Immunoregulation and Cancer: Food Design for Targeting Disease
Ahn-Jarvis, J., Parihar, A., & Doseff, A. (2019) · Antioxidants · doi:10.3390/antiox8070202 · Cited by 95
Subaran, S. C., Sauder, M. A., Chai, W., Jahn, L. A., Fowler, D. E., Aylor, K. W., Basu, A., & Liu, Z. (2014) · Clinical Science · doi:10.1042/cs20130708 · Cited by 95
Incretins and the development of type 2 diabetes
Meier, J. J., & Nauck, M. A. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0034-7 · Cited by 110
Self-citationEllrichmann, M., Kapelle, M., Ritter, P. R., Holst, J. J., Herzig, K.-H., Schmidt, W. E., Schmitz, F., & Meier, J. J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0924 · Cited by 94
Self-citationIncretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93
Flint, A., Kapitza, C., Hindsberger, C., & Zdravkovic, M. (2011) · Advances in Therapy · doi:10.1007/s12325-010-0110-x · Cited by 91
The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1
Nauck, M. A., & El-Ouaghlidi, A. (2005) · Diabetologia · doi:10.1007/s00125-005-1704-8 · Cited by 93
Self-citationMeier, J. J., Weyhe, D., Michaely, M., Senkal, M., Zumtobel, V., Nauck, M. A., Holst, J. J., Schmidt, W. E., & Gallwitz, B. (2004) · Critical Care Medicine · doi:10.1097/01.ccm.0000114811.60629.b5 · Cited by 89
Self-citationMetabolic consequences of a 50% partial pancreatectomy in humans
Menge, B., Schrader, H., Breuer, T. G. K., Dabrowski, Y., Uhl, W. H., Schmidt, W. E., & Meier, J. J. (2008) · Diabetologia · doi:10.1007/s00125-008-1219-1 · Cited by 96
Self-citationMurage, E. N., Gao, G., Bisello, A., & Ahn, J.-M. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100602m · Cited by 87
Diabetes and obesity: therapeutic targeting and risk reduction – a complex interplay
Niswender, K. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01175.x · Cited by 87
Caffeine-inducible gene switches controlling experimental diabetes
Bojar, D., Scheller, L., Hamri, G. C., Xie, M., & Fussenegger, M. (2018) · Nature Communications · doi:10.1038/s41467-018-04744-1 · Cited by 93
Meier, J. J., Gallwitz, B., Kask, B., Deacon, C. F., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s220 · Cited by 85
Self-citationAcarbose attenuates the hypotensive response to sucrose and slows gastric emptying in the elderly
Gentilcore, D., Bryant, B., Wishart, J. M., Morris, H. A., Horowitz, M., & Jones, K. L. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.05.019 · Cited by 87
Glucagon-like peptide 1 (GLP-1) suppresses ghrelin levels in humans via increased insulin secretion
Hagemann, D., Holst, J. J., Gethmann, A., Banasch, M., Schmidt, W. E., & Meier, J. J. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2007.03.002 · Cited by 103
Self-citationRelationship Between Control of Glycemia and Gastric Emptying Disturbances in Diabetes Mellitus
Halland, M., & Bharucha, A. E. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.11.021 · Cited by 84
Glucagon-Like Peptide-1-Based Therapies for the Treatment of Type 2 Diabetes Mellitus
Gallwitz, B. (2005) · Treatments in Endocrinology · doi:10.2165/00024677-200504060-00005 · Cited by 93
Self-citationGlucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity
Anandhakrishnan, A., & Korbonits, M. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i20.572 · Cited by 82
Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide
Meier, J. J., & Nauck, M. A. (2004) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2004.08.007 · Cited by 82
Self-citationMeier, J. J., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00289.2007 · Cited by 77
Self-citationFederico, A., Dallio, M., Tolone, S., Gravina, A. G., Patrone, V., Romano, M., Tuccillo, C., Mozzillo, A. L., Amoroso, V., Misso, G., et al. (2016) · PubMed · Cited by 92
Jones, K. L., Huynh, L. Q., Hatzinikolas, S., Rigda, R. S., Phillips, L. K., Pham, H. T., Marathe, C. S., Wu, T., Malbert, C. H., Stevens, J. E., et al. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13956 · Cited by 76
Nicolaus, M., Brödl, J., Linke, R., Woerle, H.-J., Göke, B., & Schirra, J. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0841 · Cited by 73
Kojima, M., Takahashi, H., Kuwashiro, T., Tanaka, K., Mori, H., Ozaki, I., Kitajima, Y., Matsuda, Y., Ashida, K., Eguchi, Y., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165722 · Cited by 69
“Furthermore, GLP-1 slows gastrointestinal motility and increases satiety with reduced food intake [9].”
BackgroundArakawa, M., Ebato, C., Mita, T., Fujitani, Y., Shimizu, T., Watada, H., Kawamori, R., & Hirose, T. (2008) · Metabolism · doi:10.1016/j.metabol.2008.04.027 · Cited by 71
Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update)
Gallwitz, B. (2007) · Drugs of Today · doi:10.1358/dot.2007.43.11.1157620 · Cited by 66
Self-citation
Metadata
- Authors
- Meier, J. J., Gallwitz, B., Salmen, S., Goetze, O., Holst, J. J., Schmidt, W. E., & Nauck, M. A.
- Affiliations
- St. Josef-Hospital (DE)
- University of Copenhagen (DK)
- Diabeteszentrum Bad Lauterberg (DE)
- Corresponding author
- Meier, Juris J.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2003-06
- Volume
- 88
- Issue
- 6
- Pages
- 2719-2725
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1987182389
- Cited by
- 369
- References
- 39
- Citations by year
- 2026: 9 · 2025: 7 · 2024: 10 · 2023: 7 · 2022: 7 · 2021: 10 · 2020: 11 · 2019: 13 · 2018: 16 · 2017: 14 · 2016: 12 · 2015: 20 · 2014: 31 · 2013: 18 · 2012: 18
- FWCI
- 10.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon-like peptide-1, type 2 diabetes, glucose homeostasis, gastric emptying, insulin secretion, C-peptide, glucagon secretion, dose-response relationship, solid meal, breath test, intravenous infusion
- MeSH terms
- Aged, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Fasting, Female, Gastric Emptying, Glucagon, Humans, Injections, Intravenous, Male, Middle Aged, Osmolar Concentration, Peptide Fragments, Protein Precursors, Time Factors, Postprandial Period, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.